摘要
目的:观察自拟脂肝方治疗脾虚痰湿型非酒精性脂肪肝的临床疗效及安全性。方法:采用非盲法随机对照设计,将60例患者随机分为2组各30例,治疗组给予自拟脂肝方治疗,对照组给予立普妥治疗,采用尼莫地平法评价2组主要症状的变化,同时评价B超、血脂、肝功能变化;并记录与药物相关的不良反应。结果:按尼莫地平法评价疗效,总有效率治疗组为83.33%,对照组为56.67%,2组比较,差异有显著性意义(P<0.05);临床症状及生存质量改善方面,治疗组疗效均优于对照组,差异均有显著性意义(P<0.05);治疗组未见与药物有关的不良反应。结论:脂肝方治疗脾虚痰湿型非酒精性脂肪肝疗效肯定,且无毒副反应,值得临床推广应用。
Objective:To observe the therapeutic effect and safety of self-pre- pared Zhigan Prescription(ZP)for the treatment of non-alcoholic fatty liver.Moth- ods:A non-blind randomized trial was carried out in 60 patients with non-alco- hohe fatty liver.The patients were equally randomized into the treatment group (receiving ZP)and the control group(receiving lipitor).The changes of main symp- toms were evaluated with the method of nimodipine.Meanwhile,the changes of B- type ultrasound,blood lipid levels and hepatic function were observed,and the ad- verse reactions of the drugs were monitored.Results:The total effective rate was 83.33% in the treatment group and 56.67% in the control group(P<0.05).The treatment group showed a better effect on relieving symptoms and improving life qual- ity than the control group(P>0.05).No obvious adverse reactions was found in the treatment group.Conclusion:ZP exerts a certain effect for the treatment of non-alcoholic fatty liver with spleen deficiency and phlegm-damp retention,and has no obvious toxic and side effects.
出处
《新中医》
CAS
北大核心
2007年第8期30-32,共3页
New Chinese Medicine
